V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022204 | 220020949 | 1.72 | 87.5 | Curative (C) | 2019-08-20 | 2019-10-04 | Alemtuzumab cond (RI ALLO CAMP100) | Y | N | 220031813 | ALEMTUZUMAB |
| 220022205 | 220008469 | 1.68 | null | Curative (C) | 2017-05-02 | 2017-08-09 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 220032105 | ALEMTUZUMAB |
| 220022206 | 220008474 | null | 78 | null | 2014-06-10 | 2014-06-22 | PACLITAXEL | 2 | N | 220032108 | PACLITAXEL |
| 220022207 | 220008496 | 1.58 | 58.91 | Palliative (P) | 2015-07-16 | 2015-07-16 | Alemtuzumab + Cyclophos TBI Allo | 2 | N | 220032156 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220022208 | 220008507 | 1.64 | 48.1 | Curative (C) | 2014-11-08 | 2014-12-13 | CLOFARABINE + DAUNORUBICIN | N | null | 220032159 | ARSENIC TRIOXIDE |
| 220022209 | 220008586 | 1.86 | 87.1 | Curative (C) | 2015-10-07 | 2017-10-13 | DABRAFENIB + TRAMETINIB | 2 | N | 220032405 | CETUXIMAB |
| 220022210 | 220014653 | 1.76 | 69 | Curative (C) | null | 2016-10-30 | CYTARABINE + FLUDARABINE + IDARUBICIN | 02 | N | 220032532 | TRASTUZUMAB |
| 220022211 | 220019904 | null | 48.1 | Curative (C) | 2016-04-02 | 2017-06-27 | LENALIDOMIDE | 2 | null | 220033250 | CVP R |
| 220022212 | 220018085 | 1.6 | 63.9 | Curative (C) | 2018-02-05 | 2018-02-05 | BUSULFAN + MELPHALAN | N | N | 220033807 | LENALIDOMIDE |
| 220022213 | 220009063 | null | 72.8 | null | 2017-08-08 | 2017-09-04 | Fludarabine IV | 02 | N | 220034115 | DAUNORUBICIN + VNCRISTINE |
| 220022214 | 220009162 | 1.75 | 75 | Palliative (P) | 2014-11-29 | 2015-07-16 | DACTINOMYCIN | N | N | 220034495 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA |
| 220022217 | 220009411 | 1.67 | 86.2 | Palliative (P) | 2015-12-06 | 2016-01-07 | Bendamustine+Rituximab(Sub Courses) | N | Y | 220035549 | CHOP R |
| 220022218 | 220022119 | 1.75 | null | Curative (C) | 2016-04-11 | 2016-04-18 | MITOXANTRONE + TRETINOIN | null | N | 220036062 | CYTARABINE IT + METHOTREXATE |
| 220022219 | 220009513 | 1.83 | 63.6 | Disease modification (D) | 2016-05-10 | 2016-06-28 | ALL UKALL2011 TRIAL | N | N | 220036121 | ARSENIC TRIOXIDE + ATRA |
| 220022220 | 220009581 | 1.5 | 64.1 | Disease modification (D) | 2019-01-28 | 2019-02-25 | MERCAPTOPURINE + METHOTREXATE | N | N | 220036432 | EOX |
| 220022221 | 220009645 | null | null | Disease modification (D) | 2015-11-11 | 2015-11-11 | DA-EPOCH-R | Y | N | 220036641 | METHOTREXATE HIGH DOSE |
| 220022222 | 220009693 | null | 89.9 | null | 2018-08-05 | 2018-08-05 | CAPECITABINE + TEMOZOLOMIDE | N | N | 220004682 | CAPECITABINE |
| 220022223 | 220009717 | 1.65 | 100 | Curative (C) | null | 2019-04-19 | ALL UKALL60+ TRIAL | 2 | N | 220018242 | MERCAPTOPURINE |
| 220022226 | 220004370 | null | 108.2 | Disease modification (D) | 2014-06-19 | 2014-07-17 | Imatinib 400mg | 02 | N | 220007789 | IMATINIB |
| 220022228 | 220004504 | 1.66 | 71.1 | Curative (C) | 2014-09-29 | 2014-10-01 | CYTARABINE + DAUNORUBICIN | N | N | 220010889 | DA |
| 220022229 | 220004541 | null | 0 | null | 2017-05-06 | 2017-05-08 | CYTARABINE + DAUNORUBICIN | N | N | 220011747 | DA |
| 220022232 | 220005087 | null | 0 | Disease modification (D) | 2018-01-26 | 2018-01-28 | Nilotinib | N | N | 220020158 | NILOTINIB |
| 220022233 | 220005094 | 1.68 | 73 | Curative (C) | 2018-08-13 | 2018-08-18 | Cytarabine High Dose | 99 | null | 220020160 | CYTARABINE HIGH DOSE |
| 220022234 | 220012741 | null | null | null | null | 2018-07-18 | Nilotinib | 2 | null | 220020414 | NILOTINIB |
| 220022235 | 220005220 | 1.64 | 75.8 | Curative (C) | 2017-09-30 | 2018-01-04 | Cytarabine High Dose | N | N | 220020435 | CYTARABINE HIGH DOSE |
| 220022238 | 220005316 | null | null | Disease modification (D) | 2014-12-07 | 2014-12-31 | Nilotinib | 2 | N | 220020591 | NILOTINIB |
| 220022239 | 220019361 | 1.63 | 102.7 | Curative (C) | null | 2014-04-09 | AML17 TRIAL | N | N | 220020646 | AML17 TRIAL |
| 220022240 | 220005354 | 1.7 | 47.6 | Curative (C) | 2019-12-02 | 2020-01-12 | AML17 TRIAL | N | null | 220020673 | AML17 TRIAL |
| 220022241 | 220017130 | 1.61 | 62.4 | Curative (C) | 2019-01-11 | 2019-01-14 | AML17 TRIAL | 02 | N | 220021572 | AML17 TRIAL |
| 220022242 | 220005762 | 1.95 | 92.8 | Curative (C) | 2017-09-26 | 2017-11-08 | AML17 TRIAL | N | N | 220021789 | AML17 TRIAL |
| 220022243 | 220013380 | 1.66 | 86 | Curative (C) | 2014-04-03 | 2014-05-17 | FLAG + Idarubicin | null | N | 220023793 | FLAG + IDARUBICIN |
| 220022244 | 220020743 | 1.67 | 55 | Curative (C) | 2018-10-09 | 2018-12-23 | FLAG + Idarubicin | Y | N | 220023821 | FLAG + IDARUBICIN |
| 220022245 | 220017378 | null | null | Palliative (P) | 2018-02-05 | 2018-08-23 | Hydroxycarbamide | 2 | null | 220024528 | HYDROXYCARBAMIDE |
| 220022246 | 220006499 | 1.77 | 85.2 | Curative (C) | null | 2019-11-20 | null | N | N | 220024708 | NOT MATCHED |
| 220022247 | 220007216 | 1.77 | 72.45 | Palliative (P) | 2015-05-10 | 2015-05-11 | CYTARABINE | N | N | 220027691 | CYTARABINE |
| 220022248 | 220007321 | 0 | 60.5 | Disease modification (D) | 2017-02-09 | 2017-02-13 | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | N | N | 220028203 | NOT MATCHED |
| 220022250 | 220007624 | null | 47.3 | Disease modification (D) | 2014-12-31 | 2015-01-06 | Amsacrine + ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) + BUSULFAN + CYTARABINE + FLUDARABINE | 2 | N | 220029445 | NOT MATCHED |
| 220022251 | 220007749 | null | 12.8 | Curative (C) | 2017-06-16 | 2017-07-31 | Amsacrine + ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) + BUSULFAN + CYTARABINE + FLUDARABINE | N | N | 220029817 | NOT MATCHED |
| 220022252 | 220014350 | 0 | 80.2 | null | 2014-06-13 | 2014-12-16 | CYTARABINE | 2 | N | 220030353 | CYTARABINE |
| 220022253 | 220007948 | 1.62 | 80 | Disease modification (D) | 2018-11-13 | 2018-11-16 | Rituximab (Maintenance) | 02 | N | 220030435 | RITUXIMAB |
| 220022254 | 220017838 | 0 | 51.7 | Curative (C) | 2016-09-07 | 2016-09-24 | Rituximab (Maintenance) | N | N | 220030471 | RITUXIMAB |
| 220022255 | 220007965 | 1.74 | null | Curative (C) | 2019-02-05 | 2019-02-05 | Rituximab | N | N | 220030475 | RITUXIMAB |
| 220022256 | 220007971 | null | 69.4 | Curative (C) | 2018-05-25 | 2018-07-05 | AML 18 TRIAL | 01 | null | 220030478 | AML18 TRIAL |
| 220022257 | 220007984 | 1.65 | 9.2 | Curative (C) | 2015-02-23 | 2015-03-03 | RUXOLITINIB | Y | N | 220030497 | RUXOLITINIB |
| 220022258 | 220008090 | 1.75 | null | Curative (C) | 2018-10-22 | 2018-11-20 | IDARUBICIN + TRETINOIN | 02 | N | 220030779 | IDARUBICIN + TRETINOIN |
| 220022259 | 220014446 | null | 88.8 | Curative (C) | 2019-11-02 | 2019-11-15 | RUXOLITINIB | N | N | 220030955 | RUXOLITINIB |
| 220022260 | 220008241 | null | 86.8 | Curative (C) | 2015-05-10 | 2015-06-03 | Triple Intrathecal | null | N | 220031302 | TRIPLE INTRATHECAL |
| 220022261 | 220008266 | null | 53 | Palliative (P) | 2018-09-28 | 2018-09-28 | Cyclophosphamide TBI Allograft | 02 | N | 220031415 | CYCLOPHOSPHAMIDE |
| 220022262 | 220020949 | 1.57 | null | Curative (C) | 2019-10-04 | 2019-10-04 | UKALL14- Intens/CNS Proph | N | N | 220031813 | GEMCARBO |
| 220022263 | 220008470 | null | 73.3 | Not known (9) | 2017-12-14 | 2017-12-19 | CARBOPLATIN + PACLITAXEL | 2 | N | 220032105 | CARBOPLATIN + PACLITAXEL |